The trial looks at a new drug, LEO 138559, for the treatment of moderate to severe eczema.
Eczema is a chronic disease that causes inflammation, redness and irritation of the skin.
The NHS Trust said researchers did not know what caused eczema, but they did know that genes, the immune system and the environment played a role in the disease.
“We are really proud to have recruited the first patient in the UK for this exciting Phase II commercial clinical trial,” said Dr Halpern.
“Our success in previous clinical trials has led to major pharmaceutical companies actively seeking to work with us and bring huge benefits to our local population.”